All In Biotech

Free tool

FAERS Monitor: Cyanokit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022041 or its brand name (Cyanokit, Hydroxocobalamin). Reports on generic versions are filed under their own applications.

Reports

4,238

Serious

3,876

91% of reports

Hospitalization

1,664

Death reported

315

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • acute kidney injury211
  • nausea207
  • diarrhoea205
  • dyspnoea190
  • dizziness178
  • vomiting167
  • off label use166
  • malaise151
  • hyponatraemia138
  • fatigue136
  • confusional state129
  • rash120
  • pruritus114
  • somnolence114
  • drug ineffective113

Reports by year received

View as table
YearReports
20045
20059
200611
200719
200842
200932
201032
201177
201285
201398
2014149
2015152
2016218
2017252
2018346
2019393
2020377
2021278
2022320
2023350
2024368
2025305
2026319

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,921 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyponatraemiaSignal13812.210.31,407
acute kidney injurySignal2116.96.01,055
confusional stateSignal1294.03.3285
somnolenceSignal1142.82.3132
dizziness1781.81.560
vomiting1671.81.556
malaise1511.71.545
dyspnoea1901.71.451
diarrhoea2051.61.444
pruritus1141.51.217
rash1201.41.112
nausea2071.31.114
off label use1660.90.81
fatigue1360.90.73
drug ineffective1130.40.493

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.